Inovio Pharmaceuticals (INO) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Inovio Pharmaceuticals (INO) over the last 17 years, with Q3 2025 value amounting to -$50.8 million.
- Inovio Pharmaceuticals' Enterprise Value rose 4009.39% to -$50.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$50.8 million, marking a year-over-year increase of 4009.39%. This contributed to the annual value of -$94.1 million for FY2024, which is 3522.54% up from last year.
- Latest data reveals that Inovio Pharmaceuticals reported Enterprise Value of -$50.8 million as of Q3 2025, which was up 4009.39% from -$47.5 million recorded in Q2 2025.
- Inovio Pharmaceuticals' Enterprise Value's 5-year high stood at -$47.5 million during Q2 2025, with a 5-year trough of -$518.6 million in Q1 2021.
- In the last 5 years, Inovio Pharmaceuticals' Enterprise Value had a median value of -$194.9 million in 2023 and averaged -$226.1 million.
- Its Enterprise Value has fluctuated over the past 5 years, first crashed by 9462.08% in 2021, then skyrocketed by 5693.82% in 2025.
- Inovio Pharmaceuticals' Enterprise Value (Quarter) stood at -$401.3 million in 2021, then skyrocketed by 36.96% to -$253.0 million in 2022, then surged by 42.57% to -$145.3 million in 2023, then soared by 35.23% to -$94.1 million in 2024, then soared by 46.02% to -$50.8 million in 2025.
- Its last three reported values are -$50.8 million in Q3 2025, -$47.5 million for Q2 2025, and -$68.4 million during Q1 2025.